About Arkis BioSciences
Arkis BioSciences is a Healthcare company based in Knoxville (United States) founded in 2011, and was acquired by Integra LifeSciences in July 2019. Surgical instrumentation for shunt surgeries. Arkis BioSciences has raised $9.38 million across 3 funding rounds from investors including Integra LifeSciences, Innova Memphis and The Lighthouse Fund. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its competitors include CoAxia, Sequent Medical and Metactive Medical; 3 of its 3 listed competitors have raised funding.
Company details
Arkis BioSciences develops technology for the neurosurgical treatments for intracranial hypertension arising from hydrocephalus, traumatic brain injury, hemorrhagic stroke and similar disorders. Their product offering includes Tunneling Guidewire Kit - shunt passer that combines a tunneling instrument with the precision of guidewire steering; Endexo molecule - a self-locating fluoro-oligomeric polymer that results in a passivated surface, thereby reducing protein adsorption, platelet adhesion and activation, and thrombus formation in catheter lumens.
- Headquarters Knoxville, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website arkisbiosciences.com
- Social LinkedIn
- Acquired by Integra LifeSciences (Jul 2019)
- Total Equity Funding$9.38M (USD)
in 3 rounds
- Latest Funding Round$4.48M (USD), Series A
Jan 2018
- InvestorsIntegra LifeSciences
& 3 more
- Acquired byIntegra LifeSciences
(Jul 2019)
Funding Insights of Arkis BioSciences
Arkis BioSciences has successfully raised a total of $9.38M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4.48 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.38M
- Total Rounds 3
- Last Round Series A — $4.48M
- First Round $1.5M
(Mar 2013)
- Investors Count 3
All 3 funding rounds of Arkis BioSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $4.48M | Series A | – | – | – |
| Jun 2016 | $3.4M | Series A | – | Innova Memphis | |
| Mar 2013 | $1.5M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Arkis BioSciences
Arkis BioSciences has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Integra LifeSciences, Innova Memphis and The Lighthouse Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in high-growth technology companies. | innovamemphis.com | Memphis, United States | ||
| lhfknox.com | ||||
| theangelcapitalgroup.com | ||||
Diversified medical devices are developed for healthcare applications. | 1989 | integralife.com | Plainsboro, United States |
Investor details for Arkis BioSciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Arkis BioSciences
4 dated milestones of Arkis BioSciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Arkis BioSciences is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series A, of $4.5M.
- Exit Acquired by Integra LifeSciences.
Competitors of Arkis BioSciences
Arkis BioSciences has 3 listed competitors in our database, 3 of them funded. They include CoAxia, Sequent Medical and Metactive Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| coaxia.com | 1999 | Maple Grove, United States | $72.6M | Catheter-based treatment for cerebral ischemia | ||
| sequentmedical.com | 2007 | Aliso Viejo, United States | $65.26M | 1,028 | Catheter-based neurovascular devices for aneurysm treatment are developed. | |
| metactivemedical.com | 2011 | Olathe, United States | $4.7M | 31 | Endovascular devices are developed for peripheral and neurovascular disease treatments. |
Detailed competitors of Arkis BioSciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Arkis BioSciences (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arkis Biosciences
Complete news archive for Arkis BioSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arkis BioSciences
Arkis BioSciences was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Arkis BioSciences is headquartered in Knoxville, United States. It is registered at Knoxville, Tennessee, United States.
Arkis BioSciences is a funded company, having raised a total of $9.38M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Mar 2013.
Arkis BioSciences develops technology for the neurosurgical treatments for intracranial hypertension arising from hydrocephalus, traumatic brain injury, hemorrhagic stroke and similar disorders. Their product offering includes Tunneling Guidewire Kit - shunt passer that combines a tunneling instrument with the precision of guidewire steering; Endexo molecule - a self-locating fluoro-oligomeric polymer that results in a passivated surface, thereby reducing protein adsorption, platelet adhesion and activation, and thrombus formation in catheter lumens.
Arkis BioSciences's top competitors include Sequent Medical, Metactive Medical and CoAxia.
Arkis BioSciences has 4 investors. Key investors include Integra LifeSciences, Innova Memphis, The Lighthouse Fund, and Angel Capital Group.
Yes. Arkis BioSciences was acquired by Integra LifeSciences in July 2019.